Drugs / ALD-451
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01639612 | Jun 2012 → Mar 2016 | malignant glioma | Henry Friedman | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALD-451 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01639612 ↗ |
| Modality | Cell therapy | “Autologous bone marrow derived ALD-451 cells administered intravenously following surgery, radiation therapy and temozolomide” NCT01639612 ↗ |
| Route | Intravenous | “ALD-451 will be administered through a peripheral IV” NCT01639612 ↗ |